GSK (NYSE:GSK) Cut to “Buy” at StockNews.com

GSK (NYSE:GSK) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Sunday.

GSK has been the subject of a number of other reports. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Seven investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, GSK presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Up 1.4 %

NYSE:GSK opened at $33.93 on Friday. GSK has a 1 year low of $32.83 and a 1 year high of $45.92. The stock has a 50-day moving average price of $34.67 and a two-hundred day moving average price of $38.35. The stock has a market cap of $70.32 billion, a price-to-earnings ratio of 22.03, a PEG ratio of 1.52 and a beta of 0.63. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98.

Hedge Funds Weigh In On GSK

A number of large investors have recently modified their holdings of GSK. FMR LLC increased its position in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after acquiring an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC raised its stake in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Primecap Management Co. CA boosted its holdings in shares of GSK by 2.4% in the 3rd quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after buying an additional 342,365 shares during the last quarter. Provident Trust Co. grew its stake in shares of GSK by 1.7% in the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after buying an additional 66,765 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC increased its holdings in GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after buying an additional 833,080 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.